Close Menu

CytRx Hires New York Area PR, IR Firm

CytRx has hired The Investor Relations Group to handle its public relations and investor relations work, RNAi News has learned.

Tom Caden of IRG confirmed the companies’ relationship, noting that his firm has been working for CytRx for “about two or three weeks.” Caden noted that he is handling IR duties for the RNAi drug developer.

CytRx president and CEO Steven Kriegsman declined comment.


Dharmacon, Bayer Expand siRNA Reagent Deal

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Russia says its candidate SARS-CoV-2 vaccine has a very high efficacy rate in an initial analysis of clinical trial data, according to the Financial Times.

Wired reports on a microbial analysis of sketches drawn by Leonardo DaVinci.

A new survey explores coronavirus vaccine hesitancy among Black and Latino individuals, the Washington Post reports.

In Nucleic Acids Research this week: the Aging Atlas database, a database of human metagenome-related metadata, and more.

Dec
03
Sponsored by
Mission Bio

Recent work by many investigators has discovered that over the course of aging, hematopoietic stem cells (HSCs) commonly undergo clonal expansion. 

Dec
10
Sponsored by
Tecan

CRISPR has developed into a core tool to facilitate genome editing, inspiring transformative ideas in engineering biology.